Active substance
Results for the substance ertugliflozin
2 results
About this active substance
Ertugliflozin is an antidiabetic medication from the SGLT2 inhibitor class (sodium-glucose co-transporter 2 inhibitors) used for the treatment of type 2 diabetes mellitus. It helps lower blood sugar levels by removing excess glucose from the blood through the urine.
The mechanism of action of ertugliflozin involves inhibiting glucose reabsorption in the renal tubules, leading to increased glucose excretion in the urine (glycosuria). Additionally, the medication may contribute to weight loss and blood pressure reduction, providing additional benefits for patients with type 2 diabetes.
Ertugliflozin is taken orally, usually once daily, with or without food. It is used either as monotherapy or in combination with other antidiabetic medications, such as metformin or insulin.
Common side effects include urinary tract infections, genital infections (especially in women), excessive thirst, frequent urination, and, in rare cases, diabetic ketoacidosis. It may also increase the risk of dehydration, particularly in elderly patients or those taking diuretics.
Patients should strictly follow their doctor’s instructions and regularly monitor their blood sugar levels. Ertugliflozin is not recommended for patients with severe renal impairment or those at high risk of diabetic ketoacidosis. Adequate hydration is important during treatment.
The mechanism of action of ertugliflozin involves inhibiting glucose reabsorption in the renal tubules, leading to increased glucose excretion in the urine (glycosuria). Additionally, the medication may contribute to weight loss and blood pressure reduction, providing additional benefits for patients with type 2 diabetes.
Ertugliflozin is taken orally, usually once daily, with or without food. It is used either as monotherapy or in combination with other antidiabetic medications, such as metformin or insulin.
Common side effects include urinary tract infections, genital infections (especially in women), excessive thirst, frequent urination, and, in rare cases, diabetic ketoacidosis. It may also increase the risk of dehydration, particularly in elderly patients or those taking diuretics.
Patients should strictly follow their doctor’s instructions and regularly monitor their blood sugar levels. Ertugliflozin is not recommended for patients with severe renal impairment or those at high risk of diabetic ketoacidosis. Adequate hydration is important during treatment.